Lung cancer. 1: prevention of lung cancer.
PDF (113K)
Journal: 2002/December - Thorax
ISSN: 0040-6376
PUBMED: 12403886
Abstract:
Cancer of the lung causes more deaths from cancer worldwide than at any other site. The environmental, genetic, and dietary risk factors are discussed and progress in chemoprevention is reviewed. A better understanding of the molecular events that occur during carcinogenesis has opened up new areas of research in cancer prevention and a number of biochemical markers of high risk individuals have been identified. It is predicted that greater success in chemoprevention will be achieved in the next decade than in the last.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(1)
References
(112)
Diseases
(1)
Chemicals
(3)
Organisms
(1)
Processes
(1)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Thorax 57(11): 994-999
PMID: 12403886

Lung cancer • 1: Prevention of lung cancer

Full Text

The Full Text of this article is available as a PDF (113K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997 May 3;349(9061):1269–1276. [PubMed] [Google Scholar]
  • Jemal Ahmedin, Thomas Andrea, Murray Taylor, Thun Michael. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23–47. [PubMed] [Google Scholar]
  • Levi F, La Vecchia C, Lucchini F, Negri E. Cancer mortality in Europe, 1990-92. Eur J Cancer Prev. 1995 Oct;4(5):389–417. [PubMed] [Google Scholar]
  • Cole P, Rodu B. Declining cancer mortality in the United States. Cancer. 1996 Nov 15;78(10):2045–2048. [PubMed] [Google Scholar]
  • Shopland DR, Hartman AM, Gibson JT, Mueller MD, Kessler LG, Lynn WR. Cigarette smoking among U.S. adults by state and region: estimates from the current population survey. J Natl Cancer Inst. 1996 Dec 4;88(23):1748–1758. [PubMed] [Google Scholar]
  • Peto R, Lopez AD, Boreham J, Thun M, Heath C, Jr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996 Jan;52(1):12–21. [PubMed] [Google Scholar]
  • Stellman SD, Takezaki T, Wang L, Chen Y, Citron ML, Djordjevic MV, Harlap S, Muscat JE, Neugut AI, Wynder EL, et al. Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193–1199. [PubMed] [Google Scholar]
  • Chollat-Traquet C. Tobacco or health: a WHO programme. Eur J Cancer. 1992;28(2-3):311–315. [PubMed] [Google Scholar]
  • Gong YL, Koplan JP, Feng W, Chen CH, Zheng P, Harris JR. Cigarette smoking in China. Prevalence, characteristics, and attitudes in Minhang District. JAMA. 1995 Oct 18;274(15):1232–1234. [PubMed] [Google Scholar]
  • Wald NJ, Nanchahal K, Thompson SG, Cuckle HS. Does breathing other people's tobacco smoke cause lung cancer? Br Med J (Clin Res Ed) 1986 Nov 8;293(6556):1217–1222.[PMC free article] [PubMed] [Google Scholar]
  • Spitzer WO, Lawrence V, Dales R, Hill G, Archer MC, Clark P, Abenhaim L, Hardy J, Sampalis J, Pinfold SP, et al. Links between passive smoking and disease: a best-evidence synthesis. A report of the Working Group on Passive Smoking. Clin Invest Med. 1990 Feb;13(1):17–46. [PubMed] [Google Scholar]
  • Cardenas VM, Thun MJ, Austin H, Lally CA, Clark WS, Greenberg RS, Heath CW., Jr Environmental tobacco smoke and lung cancer mortality in the American Cancer Society's Cancer Prevention Study. II. Cancer Causes Control. 1997 Jan;8(1):57–64. [PubMed] [Google Scholar]
  • Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst. 1993 Mar 17;85(6):457–464. [PubMed] [Google Scholar]
  • Lubin JH, Blot WJ. Lung cancer and smoking cessation: patterns of risk. J Natl Cancer Inst. 1993 Mar 17;85(6):422–423. [PubMed] [Google Scholar]
  • Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapleton P, Weiss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 1993 May 15;53(10 Suppl):2313–2318. [PubMed] [Google Scholar]
  • Yoshida K, Hamajima N, Kozaki Ki, Saito H, Maeno K, Sugiura T, Ookuma K, Takahashi T. Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):403–405. [PubMed] [Google Scholar]
  • Risser NL. Prevention of lung cancer: the key is to stop smoking. Semin Oncol Nurs. 1996 Nov;12(4):260–269. [PubMed] [Google Scholar]
  • Koh HK. An analysis of the successful 1992 Massachusetts tobacco tax initiative. Tob Control. 1996 Autumn;5(3):220–225.[PMC free article] [PubMed] [Google Scholar]
  • Spitz MR, Bondy ML. Genetic susceptibility to cancer. Cancer. 1993 Aug 1;72(3 Suppl):991–995. [PubMed] [Google Scholar]
  • Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst. 1996 Apr 17;88(8):496–509. [PubMed] [Google Scholar]
  • Li D, Firozi PF, Wang LE, Bosken CH, Spitz MR, Hong WK, Wei Q. Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. Cancer Res. 2001 Feb 15;61(4):1445–1450. [PubMed] [Google Scholar]
  • Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, Spitz MR. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 1997 May;18(5):967–973. [PubMed] [Google Scholar]
  • Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers GE, Tucker MA, Trump BF, Weston A, Harris CC. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):515–518. [PubMed] [Google Scholar]
  • Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993 Jul 1;53(13):2994–2999. [PubMed] [Google Scholar]
  • Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst. 1992 Mar 18;84(6):414–422. [PubMed] [Google Scholar]
  • Zhou Wei, Liu Geoffrey, Thurston Sally W, Xu Li Lian, Miller David P, Wain John C, Lynch Thomas J, Su Li, Christiani David C. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):15–21. [PubMed] [Google Scholar]
  • Hou SM, Fält S, Yang K, Nyberg F, Pershagen G, Hemminki K, Lambert B. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):133–140. [PubMed] [Google Scholar]
  • Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, Lynch PM, Amos CI. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res. 2001 Feb 15;61(4):1269–1271. [PubMed] [Google Scholar]
  • Zhou W, Thurston SW, Liu G, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):461–466. [PubMed] [Google Scholar]
  • Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):119–123. [PubMed] [Google Scholar]
  • David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911–912. [PubMed] [Google Scholar]
  • Park Jae Yong, Lee Su Yeon, Jeon Hyo-Sung, Bae Nack Chun, Chae Sang Chul, Joo Soyoung, Kim Chang Ho, Park Jae-Ho, Kam Sin, Kim In San, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):23–27. [PubMed] [Google Scholar]
  • Woodson K, Stewart C, Barrett M, Bhat NK, Virtamo J, Taylor PR, Albanes D. Effect of vitamin intervention on the relationship between GSTM1, smoking, and lung cancer risk among male smokers. Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):965–970. [PubMed] [Google Scholar]
  • Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):397–401. [PubMed] [Google Scholar]
  • Ziegler RG, Colavito EA, Hartge P, McAdams MJ, Schoenberg JB, Mason TJ, Fraumeni JF., Jr Importance of alpha-carotene, beta-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst. 1996 May 1;88(9):612–615. [PubMed] [Google Scholar]
  • Colditz GA, Stampfer MJ, Willett WC. Diet and lung cancer. A review of the epidemiologic evidence in humans. Arch Intern Med. 1987 Jan;147(1):157–160. [PubMed] [Google Scholar]
  • Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992;18(1):1–29. [PubMed] [Google Scholar]
  • Stähelin HB, Gey KF, Eichholzer M, Lüdin E, Bernasconi F, Thurneysen J, Brubacher G. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective Basel Study. Am J Epidemiol. 1991 Apr 15;133(8):766–775. [PubMed] [Google Scholar]
  • Nomura AM, Stemmermann GN, Heilbrun LK, Salkeld RM, Vuilleumier JP. Serum vitamin levels and the risk of cancer of specific sites in men of Japanese ancestry in Hawaii. Cancer Res. 1985 May;45(5):2369–2372. [PubMed] [Google Scholar]
  • Wald NJ, Thompson SG, Densem JW, Boreham J, Bailey A. Serum beta-carotene and subsequent risk of cancer: results from the BUPA Study. Br J Cancer. 1988 Apr;57(4):428–433.[PMC free article] [PubMed] [Google Scholar]
  • Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and risk of cancer. A prospective follow-up of nine years. Cancer. 1987 Jul 15;60(2):145–148. [PubMed] [Google Scholar]
  • Connett JE, Kuller LH, Kjelsberg MO, Polk BF, Collins G, Rider A, Hulley SB. Relationship between carotenoids and cancer. The Multiple Risk Factor Intervention Trial (MRFIT) Study. Cancer. 1989 Jul 1;64(1):126–134. [PubMed] [Google Scholar]
  • Greenwald P. NCI cancer prevention and control research. Prev Med. 1993 Sep;22(5):642–660. [PubMed] [Google Scholar]
  • Willett WC, Polk BF, Underwood BA, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med. 1984 Feb 16;310(7):430–434. [PubMed] [Google Scholar]
  • Stahl W, Sies H. Lycopene: a biologically important carotenoid for humans? Arch Biochem Biophys. 1996 Dec 1;336(1):1–9. [PubMed] [Google Scholar]
  • Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG, Williams AW, Moore BJ, Erdman JW., Jr cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):823–833. [PubMed] [Google Scholar]
  • Knekt P, Järvinen R, Seppänen R, Hellövaara M, Teppo L, Pukkala E, Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol. 1997 Aug 1;146(3):223–230. [PubMed] [Google Scholar]
  • Hecht SS. Chemoprevention of lung cancer by isothiocyanates. Adv Exp Med Biol. 1996;401:1–11. [PubMed] [Google Scholar]
  • Stoner GD, Morse MA. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett. 1997 Mar 19;114(1-2):113–119. [PubMed] [Google Scholar]
  • Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976 May 1;35(6):1332–1338. [PubMed] [Google Scholar]
  • Bertram JS, Kolonel LN, Meyskens FL., Jr Rationale and strategies for chemoprevention of cancer in humans. Cancer Res. 1987 Jun 1;47(11):3012–3031. [PubMed] [Google Scholar]
  • Goodman GE. Cancer prevention: chemoprevention vs dietary modifications. Prev Med. 1993 Sep;22(5):689–692. [PubMed] [Google Scholar]
  • Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, Steele VE, Lubet RA. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 1996 Oct;10(10):1471–1488. [PubMed] [Google Scholar]
  • Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. [PubMed] [Google Scholar]
  • Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, et al. Clinical development plan: piroxicam. J Cell Biochem Suppl. 1994;20:219–230. [PubMed] [Google Scholar]
  • Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, et al. Clinical development plan: sulindac. J Cell Biochem Suppl. 1994;20:240–251. [PubMed] [Google Scholar]
  • Meyskens FL, Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst. 1994 Aug 3;86(15):1122–1130. [PubMed] [Google Scholar]
  • Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, et al. Clinical development plan: 2-difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1994;20:147–165. [PubMed] [Google Scholar]
  • Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol. 1994 Apr;12(4):851–873. [PubMed] [Google Scholar]
  • Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990 Sep 20;323(12):795–801. [PubMed] [Google Scholar]
  • van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000 Jun 21;92(12):977–986. [PubMed] [Google Scholar]
  • Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18;93(8):605–618. [PubMed] [Google Scholar]
  • Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, Peters EJ, Pang AC, Fritsche HA, Jr, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol. 1994 May;12(5):937–945. [PubMed] [Google Scholar]
  • Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000;5(5):361–368. [PubMed] [Google Scholar]
  • Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Jr, Valanis B, Williams JH, Jr, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996 Nov 6;88(21):1550–1559. [PubMed] [Google Scholar]
  • Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996 Nov 6;88(21):1560–1570. [PubMed] [Google Scholar]
  • van den Brandt PA, Goldbohm RA, van 't Veer P, Bode P, Dorant E, Hermus RJ, Sturmans F. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res. 1993 Oct 15;53(20):4860–4865. [PubMed] [Google Scholar]
  • Clark LC, Combs GF, Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957–1963. [PubMed] [Google Scholar]
  • Melamed MR, Zaman MB, Flehinger BJ, Martini N. Radiologically occult in situ and incipient invasive epidermoid lung cancer: detection by sputum cytology in a survey of asymptomatic cigarette smokers. Am J Surg Pathol. 1977 Mar;1(1):5–16. [PubMed] [Google Scholar]
  • Topping DC, Griesemer RA, Nettesheim P. Quantitative assessment of generalized epithelial changes in tracheal mucosa following exposure to 7,12-dimethylbenz(a)anthracene. Cancer Res. 1979 Dec;39(12):4823–4828. [PubMed] [Google Scholar]
  • Ono J, Auer G, Caspersson T, Nasiell M, Saito T, Konaka C, Kato H, Hayata Y. Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer. 1984 Sep 15;54(6):1030–1037. [PubMed] [Google Scholar]
  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  • Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980–1981. [PubMed] [Google Scholar]
  • Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. [PubMed] [Google Scholar]
  • Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999 Jan;187(1):8–18. [PubMed] [Google Scholar]
  • Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):625–634. [PubMed] [Google Scholar]
  • Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar;16(3):1207–1217. [PubMed] [Google Scholar]
  • Humbert M, Delattre RM, Cerrina J, Dartevelle P, Simonneau G, Emilie D. Serum neopterin after lung transplantation. Chest. 1993 Feb;103(2):449–454. [PubMed] [Google Scholar]
  • Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  • D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 1992 Feb;7(2):339–346. [PubMed] [Google Scholar]
  • Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27;246(4929):491–494. [PubMed] [Google Scholar]
  • Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992 Sep 1;52(17):4799–4804. [PubMed] [Google Scholar]
  • Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res. 1994 Jan-Feb;14(1B):261–267. [PubMed] [Google Scholar]
  • Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 1999 May 15;59(10):2470–2476. [PubMed] [Google Scholar]
  • Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995 Mar 15;55(6):1365–1372. [PubMed] [Google Scholar]
  • Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994 Apr 1;54(7):1634–1637. [PubMed] [Google Scholar]
  • Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 Jun 18;89(12):857–862. [PubMed] [Google Scholar]
  • Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986 Mar 6;320(6057):84–85. [PubMed] [Google Scholar]
  • Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587–597. [PubMed] [Google Scholar]
  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. [PubMed] [Google Scholar]
  • Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. [PubMed] [Google Scholar]
  • Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995 Dec 15;55(24):6200–6209. [PubMed] [Google Scholar]
  • Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst. 1999 Feb 17;91(4):332–339. [PubMed] [Google Scholar]
  • Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891–11896.[PMC free article] [PubMed] [Google Scholar]
  • Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. [PubMed] [Google Scholar]
  • Swafford DS, Middleton SK, Palmisano WA, Nikula KJ, Tesfaigzi J, Baylin SB, Herman JG, Belinsky SA. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol. 1997 Mar;17(3):1366–1374.[PMC free article] [PubMed] [Google Scholar]
  • Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821–9826.[PMC free article] [PubMed] [Google Scholar]
  • Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000 Nov 1;60(21):5954–5958. [PubMed] [Google Scholar]
  • Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res. 2001 Oct;7(10):3127–3134. [PubMed] [Google Scholar]
  • Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000 Dec 15;89(12):2637–2645. [PubMed] [Google Scholar]
  • Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000 Nov;30(2):73–81. [PubMed] [Google Scholar]
  • Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999 Aug;14(2):412–418. [PubMed] [Google Scholar]
  • Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998 Nov 15;58(22):4997–5001. [PubMed] [Google Scholar]
  • Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998 Sep 1;58(17):3761–3764. [PubMed] [Google Scholar]
  • Hung WC, Chang HC, Pan MR, Lee TH, Chuang LY. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol. 2000 Dec;58(6):1398–1403. [PubMed] [Google Scholar]
  • Eli Y, Przedecki F, Levin G, Kariv N, Raz A. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565–571. [PubMed] [Google Scholar]
  • Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Hölscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res. 2001 Jul;7(7):1850–1855. [PubMed] [Google Scholar]
  • Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984 Aug;74(2):647–651.[PMC free article] [PubMed] [Google Scholar]
  • Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986 Aug;54(2):265–269.[PMC free article] [PubMed] [Google Scholar]
  • Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987 May;55(5):513–516.[PMC free article] [PubMed] [Google Scholar]
  • Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol. 1986 May;149(1):9–14. [PubMed] [Google Scholar]
  • Berger MS, Gullick WJ, Greenfield C, Evans S, Addis BJ, Waterfield MD. Epidermal growth factor receptors in lung tumours. J Pathol. 1987 Aug;152(4):297–307. [PubMed] [Google Scholar]
Fred Hutchinson Cancer Research Center, Swedish Medical Center Cancer Institute, Seattle, Washington, USA. gro.hsidews@namdoog.yrag
Fred Hutchinson Cancer Research Center, Swedish Medical Center Cancer Institute, Seattle, Washington, USA. gro.hsidews@namdoog.yrag
Copyright notice
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.